Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$43 Mln
P/E Ratio
--
P/B Ratio
0.37
Industry P/E
--
Debt to Equity
0.16
ROE
-0.79 %
ROCE
-67.7 %
Div. Yield
0 %
Book Value
3.71
EPS
-2.81
CFO
$-153.40 Mln
EBITDA
$-181.34 Mln
Net Profit
$-178.24 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
PepGen (PEPG)
| -55.67 | -5.08 | -13.85 | -85.67 | -- | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
PepGen (PEPG)
| -44.00 | -49.14 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 10,135.98 | 20.78 | 23.13 | |
| 302.88 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is... Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118 Read more
President, CEO, Treasurer, Secretary & Director
Dr. James G. McArthur Ph.D.
President, CEO, Treasurer, Secretary & Director
Dr. James G. McArthur Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PepGen Ltd (PEPG) stood at $ 151 Mln as on 31-Dec-24
The share price of PepGen Ltd (PEPG) is $1.68 (NASDAQ) as of 24-Apr-2025 16:00 EDT. PepGen Ltd (PEPG) has given a return of -85.67% in the last 1 years.
PepGen Ltd (PEPG) has a market capitalisation of $ 43 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of PepGen Ltd (PEPG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PepGen Ltd (PEPG) and enter the required number of quantities and click on buy to purchase the shares of PepGen Ltd (PEPG).
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
The CEO & director of Dr. James G. McArthur Ph.D.. is PepGen Ltd (PEPG), and CFO & Sr. VP is Dr. James G. McArthur Ph.D..
There is no promoter pledging in PepGen Ltd (PEPG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| PepGen Ltd (PEPG) | Ratios |
|---|---|
|
Return on equity(%)
|
-79.26
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of PepGen Ltd (PEPG) was $0 Mln.
$0.07
(
